SlideShare a Scribd company logo
Setting Specification
Limits for Impurities in
Active Pharmaceutical
Ingredient (API’s)
January, 2015
1
Points Covered
Classification of Impurities
Setting the specification limit for Organic Impurities
Setting the specification limit for Residual Solvents
Setting the specification limit for Inorganic Impurities
Setting the specification limit for the Solvents or Reagents
(Not related to API) not listed in ICH Q3C Guideline
2
Points Covered
Purpose of Module
To create awareness to the employees on setting the
specification limit for Impurities in the final API as
per the ICH Q3A and Q3C Guidelines
3
Purpose of Module
What is an Impurity:
Any component of the API that is not the chemical entity
defined as the API is called as an impurity.
Identified Impurity:
An impurity for which a structural characterisation has been
achieved.
Specified Impurity:
An impurity that is individually listed and limited with a
specific acceptance criterion in the specification. Can be
either identified or unidentified.
4
Definitions:
Definitions
Definitions:…
Unidentified Impurity:
An impurity for which a structural characterisation has not
been achieved and that is defined solely by qualitative
analytical properties (e.g. chromatographic retention time).
Unspecified Impurity:
An impurity that is limited by a general acceptance criterion,
but not individually listed with its own specific acceptance
criterion in the specification.
Qualification:
Process of acquiring and evaluating data that establishes the
biological safety of an individual impurity or a given impurity
profile at the level(s) specified.
5
Definitions
Classification of Impurities
Impurities are classified into the following
categories:
Organic impurities (API-related Impurities)
Inorganic impurities
Residual solvents
6
Organic Impurities
Organic Impurities
(API Related Impurities)
7
Organic Impurities
Organic Impurities:
Organic impurities can arise during the manufacturing
process and/or storage of the new drug substance. They
can be identified or unidentified, volatile or non-volatile,
and include:
Starting materials
By-products
Intermediates
Degradation products
8
Specification limit for Organic Impurities:
When the product is listed in Major Pharmacopoeia
like, USP or EP.
The impurity limits must comply the requirements of the
Pharmacopoeia.
If the impurity limits are different in all the pharmacopoeia,
then the stringent limit must be adopted.
The limit for any unspecified impurities must be defined as
not more than 0.10% or 0.05% based on the dosage (For
Veterinary APIs Not more than 0.20%), eventhough the
pharmacopoeia specifies the higher limit.
9
Specification Limit for Organic Impurities
Specification limit for Organic Impurities:…
Where the product is listed in Major Pharmacopoeia
like, USP or EP:...
Wherever Pharmacopeia gives a limit of more than 0.10%
or 0.05% based on the dosage (0.20% for Veterinary APIs)
for impurities in general, such limits are applicable only for
known impurities listed in the monograph.
When the pharmacopoeia contains the test for
Chromatographic purity by TLC (instead of HPLC), a suitable
HPLC, GC … method needs to be adopted specifying the
impurity limits inline with the ICH Guidelines.
10
Specification Limit for Organic Impurities
Specification limit for Organic Impurities:…
Where the product is listed in Major Pharmacopoeia
like, USP or EP:….
Thin-layer chromatography methods should only be used
for control of a specified impurity and where liquid
chromatography, gas chromatography or capillary
electrophoresis methods are inappropriate (usually due to a
lack of a suitable detection system).
11
Specification Limit for Organic Impurities
Specification limit for Organic Impurities For
Non-Pharmacopoeia APIs:
The limits must be specified as per the below table
12
Thresholds of Impurities for Human API’s
Maximum
daily dosage
Reporting
threshold
Identification
Threshold
Qualification
Threshold
< 2 g/day 0.05% 0.10% or 1.0 mg per
day intake (whichever
is lower)
0.15% or 1.0 mg per day
intake (whichever is
lower)
> 2 g/day 0.03% 0.05% 0.05%
Thresholds of Impurities for Veterinary API’s
Maximum
daily dosage
Reporting
threshold
Identification
Threshold
Qualification
Threshold
- 0.10% 0.20% 0.50%
Specification Limit for Organic Impurities
Specification limit for Organic Impurities:….
For Non Pharmacopoeia APIs:….
For the API’s having both human and veterinary applications,
the limits must be specified considering it as Human API.
If the maximum daily dosage is more than 2.0g/day, limit for
Identified and Unidentified impurities is 0.05%.
The limit for Unidentified impurity is 0.10% if the daily
dosage is ≤ 1g/day. The limit for Identified impurity is 0.15% if
the daily dosage is ≤ 0.66g/day.
If the maximum daily dosage is more than the dosages
mentioned above and less than 2g/day, the limits for Identified
and Unidentified impurities are calculated as :
% limit = (1.0 X 100)/ max daily dosage in mg
13
Specification Limit for Organic Impurities
Specification limit for Organic Impurities:….
For Non Pharmacopoeia APIs:….
For Veterinary API’s the limit for Identified and
Unidentified impurities are 0.50% and 0.20%
respectively.
Higher limits can be specified only if the Biological
safety of the impurity is established (i.e., if the impurity
is qualified).
14
Specification Limit for Organic Impurities
Residual Solvents
Residual Solvents
15
Residual Solvents
Introduction:
Residual solvents are the organic volatile chemicals that
are used or produced in the manufacture of drug
substances or excipients, or in the preparation of drug
products. The solvents are not completely removed by
practical manufacturing techniques.
Since there is no therapeutic benefit from residual
solvents, all residual solvents should be removed to the
extent possible to meet product specifications.
16
Residual Solvents
Classification of Residual Solvents by Risk
Assessment:
Class 1 solvents: Solvents to be avoided
Known human carcinogens, strongly suspected human
carcinogens, and environmental hazards.
Class 2 solvents: Solvents to be limited
Non-genotoxic animal carcinogens or possible causative
agents of other irreversible toxicity such as neurotoxicity or
teratogenicity.
Class 3 solvents: Solvents with low toxic potential
Solvents with low toxic potential to man; no health-based
exposure limit is needed. Class 3 solvents have PDEs of 50
mg or more per day.
17
Residual Solvents
Options for Describing Limits of Class 2
Solvents :
Two options are available when setting limits for Class 2
solvents.
Option 1: The concentration limits in ppm stated in ICH
Q3C Guideline can be used. They were calculated using
the formula given below, by assuming a product mass of
10 g administered daily.
1000 X PDE (mg/day)
Concentration (ppm) = ----------------------------
dose (g/day)
18
Residual Solvents
Options for Describing Limits of Class 2
Solvents :…
Option 2: The limits are calculated using the above
formula based on the PDE reported in the ICH Q3C
Guideline and the maximum daily dosage of the Drug
substance.
The limits calculated are acceptable provided that it
has been demonstrated that the residual solvent has
been reduced to the practical minimum. The limits
should be realistic in relation to analytical precision,
manufacturing capability.
19
Limits of Residual Solvents
Class 1 solvents :
20
Solvent Concentration limit
(ppm)
Benzene 2
Carbon tetrachloride 4
1,2-Dichloroethane 5
1,1-Dichloroethene 8
1,1,1-Trichloroethane 1500
Limits of Residual Solvents
Class 2 solvents :
21
Solvent Limit (ppm) Solvent Limit (ppm)
Acetonitrile 410 2-Ethoxyethanol 160
Chlorobenzene 360 Ethyleneglycol 620
Chloroform 60 Formamide 220
Cyclohexane 3880 Hexane 290
1,2-Dichloroethene 1870 Methanol 3000
Dichloromethane 600 2-Methoxyethanol 50
1,2-Dimethoxyethane 100 Methylbutyl ketone 50
N,N-Dimethylacetamide 1090 Methylcyclohexane 1180
N,N-Dimethylformamide 880 N-Methylpyrrolidone 530
1,4-Dioxane 380 Nitromethane 50
Tetrahydrofuran 720 Pyridine 200
Tetralin 100 Sulfolane 160
1,1,2-Trichloroethene 80 Toluene 890
Xylene 2170 - -
Limits of Residual Solvents
Class 3 solvents :
It is considered that amounts of these residual solvents of 50
mg per day or less (corresponding to 5000 ppm or 0.5%
under Option 1) is acceptable.
22
Solvent Solvent Solvent
Acetic acid Ethanol 3-Methyl-1-butanol
Acetone Ethyl acetate Methylethyl ketone
Anisole Ethyl ether Methylisobutyl ketone
1-Butanol Ethyl formate 2-Methyl-1-propanol
2-Butanol Formic acid Pentane
Butyl acetate Heptane 1-Pentanol
tert-Butylmethyl ether Isobutyl acetate 1-Propanol
Cumene Isopropyl acetate 2-Propanol
Dimethyl sulfoxide Methyl acetate Propyl acetate
Limits of Residual Solvents
Solvents for which No Adequate Toxicological Data was
Found:
No adequate toxicological data is found for the following
solvents.
23
Solvent Solvent
1,1-Diethoxypropane Methylisopropyl ketone
1,1-Dimethoxymethane Methyltetrahydrofuran
2,2-Dimethoxypropane Petroleum ether
Isooctane Trichloroacetic acid
Isopropyl ether Trifluoroacetic acid
Inorganic Impurities
Inorganic Impurities
24
Inorganic Impurities
Introduction:
Inorganic impurities can result from the
manufacturing process. They are normally known and
identified and include:
Reagents, ligands and catalysts
Heavy metals or other residual metals
Inorganic salts
Other materials (e.g., filter aids, charcoal)
25
Control of Inorganic Impurities
Control of the Impurities:
Detected and quantified using pharmacopoeial or other
appropriate procedures.
Carry over of the catalysts to the API must be evaluated
during the development stage.
Inclusion/exclusion from the specification must be
justified.
Acceptance criteria must be based on pharmacopoeial
or known safety standard.
Controlled by the tests Heavy Metals, Sulfated Ash, test
for specific metal….
26
Control of Inorganic Impurities
Specification limit for Heavy Metals:
As specified by Pharmacopeia wherever applicable.
Specification limit where the product is not listed in
the pharmacopoeia:
27
Control of Inorganic Impurities
Specification limit for Sulfated Ash:
As specified by Pharmacopeia wherever applicable.
When it is not listed in pharmacopoeia, must be
specified as 0.1%, unless otherwise justified.
Specification limit for Metal Catalysts:
Must be specified inline with the EMEA guideline on
metal Catalysts.
If the metal is not listed, must specify based on the
available toxicology data or any other guidance.
28
Control of Inorganic Impurities
Specification limit for some of the metal Impurities:
*The total amount of listed metals should not exceed the indicated limit
(Reference: EMEA Guideline for specification limits for metal resides)
29
Classificatio
n
Oral Exposure Parenteral Exposure
PDE (µg/day) Conc. (ppm) PDE (µg/day) Conc. (ppm)
Class IA:
Pt, Pd
100 10 10 1
Class 1B*:
Ir, Rh, Ru, Os
100 10 10 1
Class 1C:
Mo, Ni, Cr, V
250 25 25 2.5
Class 2:
Cu, Mn
2500 250 250 25
Class 3:
Fe, Zn
13000 1300 1300 130
Specification limit for Non-API related impurities not
listed in ICH Q3C Guideline
Setting the specification limit for the Solvents or
Reagents (Not related to API) not listed in ICH
Q3C Guideline
30
Specification limit for Non-API related impurities not
listed in ICH Q3C Guideline
Introduction:
The specification limit for the solvents or reagents which
are not listed in ICH Q3C must be determined based on
the Toxicological data.
Formula for the calculation of the impurity is given in the
next slide:
31
Specification limit for Non-API related impurities not
listed in ICH Q3C Guideline
Methods for Establishing Exposure Limits:
Acceptable exposure levels is calculated from the PDE
values inline with the procedure given in ICH Q3C
Guideline as below:
1000 X PDE (mg/day)
Concentration (ppm) = ----------------------------
dose (g/day)
32
Specification limit for Non-API related impurities not
listed in ICH Q3C Guideline
Calculation of the PDE Value:
Where PDE value is not available, PDE is derived from
the no-observed-effect level (NOEL), or the lowest-
observed effect level (LOEL) in the most relevant animal
study as follows:
NOEL x Weight Adjustment
PDE = -------------------------------------
F1 x F2 x F3 x F4 x F5
33
Specification limit for Non-API related impurities not
listed in ICH Q3C Guideline
Calculation of the PDE Value:…
F1 = A factor to account for extrapolation between species.
F2 = A factor of 10 to account for variability between
individuals.
F3 = A variable factor to account for toxicity studies of short-
term exposure.
F4 = A factor that may be applied in cases of severe toxicity,
e.g. non-genotoxic carcinogenicity, neurotoxicity or
teratogenicity.
F5 = A variable factor that may be applied if the no-effect
level was not established.
34
Specification limit for Non-API related impurities not
listed in ICH Q3C Guideline
A typical calculation for Establishing Exposure Limits
(Specification Limit) is attached.
35
References
References:
IMPURITIES IN NEW DRUG SUBSTANCES Q3A.
IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS
Q3C.
GUIDELINE ON THE SPECIFICATION LIMITS FOR
RESIDUES OF METAL CATALYSTS OR METAL REAGENTS.
36
Questions?
37
Thank You
38

More Related Content

PDF
Nitrosamines In Human Medicinal Products
PPTX
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
PPTX
Ir principle and factors affecting-lakshmi priya
PPTX
Methodology of organic synthesis
PPT
Dissolution-method Development-PPT
PPTX
What is a Scientific Presentation ?
PPTX
Impurities in drug substance (ich q3 a)
PPTX
In Silico methods for ADMET prediction of new molecules
Nitrosamines In Human Medicinal Products
PREDICTION AND ANALYSIS OF ADMET PROPERTIES OF NEW.pptx
Ir principle and factors affecting-lakshmi priya
Methodology of organic synthesis
Dissolution-method Development-PPT
What is a Scientific Presentation ?
Impurities in drug substance (ich q3 a)
In Silico methods for ADMET prediction of new molecules

What's hot (20)

PDF
Ich q3 d elemental impurities
PPTX
Genotoxic impurities
PPTX
Impurities ICH Q3 Guidelines Au Vivek Jain
PPTX
Residual solvents
PPTX
ICH Q3B (R2):Impurities in new drug products
PPTX
Impurities in drug substances and drug products
PPTX
ICH Q6A Specifications by Chandra Mohan
PDF
Genotoxic Impurities
PPTX
Q3A(R2)
PPT
Best techniques to control Genotoxities and impact of ICH M7 guideline
PPTX
ICH- Q3 Impurity
PDF
Nitrosamine Impurities; A Failure, Challenge & Threat
PPTX
Q3C GUIDELINE FOR RESIDUAL SOLVENTS
PPTX
Q3A(R2) IMPURITIES IN NEW DRUG SUBSTANCES
PDF
ICH Q3D - Elemental impurities in pharmaceutical products
 
PDF
Pharmaceutical impurities classification, detection &amp; characterization.
PPTX
Q3D Guideline For Elemental Impurities
PPT
Impurities in Drug Substance & in Drug Product
PPTX
ICH guidelines on impurities in new drug products.pptx
PPTX
Q3A(R2) by Anubhav Singh, M.pharm 1st Year
Ich q3 d elemental impurities
Genotoxic impurities
Impurities ICH Q3 Guidelines Au Vivek Jain
Residual solvents
ICH Q3B (R2):Impurities in new drug products
Impurities in drug substances and drug products
ICH Q6A Specifications by Chandra Mohan
Genotoxic Impurities
Q3A(R2)
Best techniques to control Genotoxities and impact of ICH M7 guideline
ICH- Q3 Impurity
Nitrosamine Impurities; A Failure, Challenge & Threat
Q3C GUIDELINE FOR RESIDUAL SOLVENTS
Q3A(R2) IMPURITIES IN NEW DRUG SUBSTANCES
ICH Q3D - Elemental impurities in pharmaceutical products
 
Pharmaceutical impurities classification, detection &amp; characterization.
Q3D Guideline For Elemental Impurities
Impurities in Drug Substance & in Drug Product
ICH guidelines on impurities in new drug products.pptx
Q3A(R2) by Anubhav Singh, M.pharm 1st Year
Ad

Similar to Setting spec limit for imps (20)

PDF
Impuritiesindrugsubstanceichq3a 160304104854 (1)
PPTX
Residual solvents
PPTX
ICH Q3 Guidelines - Impurities (Q3A - Q3E)
PPTX
Impurities in residual solvents raj presentation
PPTX
Residual solvents as impurities
PPTX
Residual Solvents, USP <467>
PPT
ICH Q3Impurities
PPTX
Impurity of drug Subatances.pptx
PPTX
ICH Q3C GUIDELINE
PPSX
Residual Solvent Limit Calculation
PPTX
Solvents used pharmaceutically(j.c)
PDF
Residual Solvents, Their Limits and PDE A Review
PPT
What is Residual solvent and its identification
PPTX
A clear understanding of ICH-Q3 IMPURITIES
PPTX
IMPURITES AND THEIR TYPES BY VIJAY KUMAR
PPTX
IMPURITY AND STABILITY STUDIES IN PHARMACEUTICAL ANALYSIS
PPTX
ICH Q3 (A) IMPURITIES IN NEW DRUG SUBSTANCES
PDF
Impurities in DS & DP
PPTX
ICH guidelines
PPTX
Ich guidlines q and s
Impuritiesindrugsubstanceichq3a 160304104854 (1)
Residual solvents
ICH Q3 Guidelines - Impurities (Q3A - Q3E)
Impurities in residual solvents raj presentation
Residual solvents as impurities
Residual Solvents, USP <467>
ICH Q3Impurities
Impurity of drug Subatances.pptx
ICH Q3C GUIDELINE
Residual Solvent Limit Calculation
Solvents used pharmaceutically(j.c)
Residual Solvents, Their Limits and PDE A Review
What is Residual solvent and its identification
A clear understanding of ICH-Q3 IMPURITIES
IMPURITES AND THEIR TYPES BY VIJAY KUMAR
IMPURITY AND STABILITY STUDIES IN PHARMACEUTICAL ANALYSIS
ICH Q3 (A) IMPURITIES IN NEW DRUG SUBSTANCES
Impurities in DS & DP
ICH guidelines
Ich guidlines q and s
Ad

Recently uploaded (20)

PPTX
HEMODYNAMICS - I DERANGEMENTS OF BODY FLUIDS.pptx
PDF
NUTRITION THROUGHOUT THE LIFE CYCLE CHILDHOOD -AGEING
PDF
Structure Composition and Mechanical Properties of Australian O.pdf
PDF
Megan Miller Colona Illinois - Passionate About CrossFit
PPTX
AI_in_Pharmaceutical_Technology_Presentation.pptx
PDF
DAY-6. Summer class. Ppt. Cultural Nursing
PPTX
NUTRITIONAL PROBLEMS, CHANGES NEEDED TO PREVENT MALNUTRITION
PPTX
Infection prevention and control for medical students
PPTX
COMMUNICATION SKILSS IN NURSING PRACTICE
PPTX
Trichuris trichiura infection
PPTX
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
PDF
Priorities Critical Care Nursing 7th Edition by Urden Stacy Lough Test Bank.pdf
PPTX
First Aid and Basic Life Support Training.pptx
PPTX
Bronchial_Asthma_in_acute_exacerbation_.pptx
PDF
A Brief Introduction About Malke Heiman
PPT
Parental-Carer-mental-illness-and-Potential-impact-on-Dependant-Children.ppt
PPTX
Medical aspects of impairment including all the domains mentioned in ICF
PDF
CHAPTER 9 MEETING SAFETY NEEDS FOR OLDER ADULTS.pdf
PPTX
Galactosemia pathophysiology, clinical features, investigation and treatment ...
PPTX
community services team project 2(4).pptx
HEMODYNAMICS - I DERANGEMENTS OF BODY FLUIDS.pptx
NUTRITION THROUGHOUT THE LIFE CYCLE CHILDHOOD -AGEING
Structure Composition and Mechanical Properties of Australian O.pdf
Megan Miller Colona Illinois - Passionate About CrossFit
AI_in_Pharmaceutical_Technology_Presentation.pptx
DAY-6. Summer class. Ppt. Cultural Nursing
NUTRITIONAL PROBLEMS, CHANGES NEEDED TO PREVENT MALNUTRITION
Infection prevention and control for medical students
COMMUNICATION SKILSS IN NURSING PRACTICE
Trichuris trichiura infection
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
Priorities Critical Care Nursing 7th Edition by Urden Stacy Lough Test Bank.pdf
First Aid and Basic Life Support Training.pptx
Bronchial_Asthma_in_acute_exacerbation_.pptx
A Brief Introduction About Malke Heiman
Parental-Carer-mental-illness-and-Potential-impact-on-Dependant-Children.ppt
Medical aspects of impairment including all the domains mentioned in ICF
CHAPTER 9 MEETING SAFETY NEEDS FOR OLDER ADULTS.pdf
Galactosemia pathophysiology, clinical features, investigation and treatment ...
community services team project 2(4).pptx

Setting spec limit for imps

  • 1. Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s) January, 2015 1
  • 2. Points Covered Classification of Impurities Setting the specification limit for Organic Impurities Setting the specification limit for Residual Solvents Setting the specification limit for Inorganic Impurities Setting the specification limit for the Solvents or Reagents (Not related to API) not listed in ICH Q3C Guideline 2 Points Covered
  • 3. Purpose of Module To create awareness to the employees on setting the specification limit for Impurities in the final API as per the ICH Q3A and Q3C Guidelines 3 Purpose of Module
  • 4. What is an Impurity: Any component of the API that is not the chemical entity defined as the API is called as an impurity. Identified Impurity: An impurity for which a structural characterisation has been achieved. Specified Impurity: An impurity that is individually listed and limited with a specific acceptance criterion in the specification. Can be either identified or unidentified. 4 Definitions: Definitions
  • 5. Definitions:… Unidentified Impurity: An impurity for which a structural characterisation has not been achieved and that is defined solely by qualitative analytical properties (e.g. chromatographic retention time). Unspecified Impurity: An impurity that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion in the specification. Qualification: Process of acquiring and evaluating data that establishes the biological safety of an individual impurity or a given impurity profile at the level(s) specified. 5 Definitions
  • 6. Classification of Impurities Impurities are classified into the following categories: Organic impurities (API-related Impurities) Inorganic impurities Residual solvents 6
  • 8. Organic Impurities Organic Impurities: Organic impurities can arise during the manufacturing process and/or storage of the new drug substance. They can be identified or unidentified, volatile or non-volatile, and include: Starting materials By-products Intermediates Degradation products 8
  • 9. Specification limit for Organic Impurities: When the product is listed in Major Pharmacopoeia like, USP or EP. The impurity limits must comply the requirements of the Pharmacopoeia. If the impurity limits are different in all the pharmacopoeia, then the stringent limit must be adopted. The limit for any unspecified impurities must be defined as not more than 0.10% or 0.05% based on the dosage (For Veterinary APIs Not more than 0.20%), eventhough the pharmacopoeia specifies the higher limit. 9 Specification Limit for Organic Impurities
  • 10. Specification limit for Organic Impurities:… Where the product is listed in Major Pharmacopoeia like, USP or EP:... Wherever Pharmacopeia gives a limit of more than 0.10% or 0.05% based on the dosage (0.20% for Veterinary APIs) for impurities in general, such limits are applicable only for known impurities listed in the monograph. When the pharmacopoeia contains the test for Chromatographic purity by TLC (instead of HPLC), a suitable HPLC, GC … method needs to be adopted specifying the impurity limits inline with the ICH Guidelines. 10 Specification Limit for Organic Impurities
  • 11. Specification limit for Organic Impurities:… Where the product is listed in Major Pharmacopoeia like, USP or EP:…. Thin-layer chromatography methods should only be used for control of a specified impurity and where liquid chromatography, gas chromatography or capillary electrophoresis methods are inappropriate (usually due to a lack of a suitable detection system). 11 Specification Limit for Organic Impurities
  • 12. Specification limit for Organic Impurities For Non-Pharmacopoeia APIs: The limits must be specified as per the below table 12 Thresholds of Impurities for Human API’s Maximum daily dosage Reporting threshold Identification Threshold Qualification Threshold < 2 g/day 0.05% 0.10% or 1.0 mg per day intake (whichever is lower) 0.15% or 1.0 mg per day intake (whichever is lower) > 2 g/day 0.03% 0.05% 0.05% Thresholds of Impurities for Veterinary API’s Maximum daily dosage Reporting threshold Identification Threshold Qualification Threshold - 0.10% 0.20% 0.50% Specification Limit for Organic Impurities
  • 13. Specification limit for Organic Impurities:…. For Non Pharmacopoeia APIs:…. For the API’s having both human and veterinary applications, the limits must be specified considering it as Human API. If the maximum daily dosage is more than 2.0g/day, limit for Identified and Unidentified impurities is 0.05%. The limit for Unidentified impurity is 0.10% if the daily dosage is ≤ 1g/day. The limit for Identified impurity is 0.15% if the daily dosage is ≤ 0.66g/day. If the maximum daily dosage is more than the dosages mentioned above and less than 2g/day, the limits for Identified and Unidentified impurities are calculated as : % limit = (1.0 X 100)/ max daily dosage in mg 13 Specification Limit for Organic Impurities
  • 14. Specification limit for Organic Impurities:…. For Non Pharmacopoeia APIs:…. For Veterinary API’s the limit for Identified and Unidentified impurities are 0.50% and 0.20% respectively. Higher limits can be specified only if the Biological safety of the impurity is established (i.e., if the impurity is qualified). 14 Specification Limit for Organic Impurities
  • 16. Residual Solvents Introduction: Residual solvents are the organic volatile chemicals that are used or produced in the manufacture of drug substances or excipients, or in the preparation of drug products. The solvents are not completely removed by practical manufacturing techniques. Since there is no therapeutic benefit from residual solvents, all residual solvents should be removed to the extent possible to meet product specifications. 16
  • 17. Residual Solvents Classification of Residual Solvents by Risk Assessment: Class 1 solvents: Solvents to be avoided Known human carcinogens, strongly suspected human carcinogens, and environmental hazards. Class 2 solvents: Solvents to be limited Non-genotoxic animal carcinogens or possible causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity. Class 3 solvents: Solvents with low toxic potential Solvents with low toxic potential to man; no health-based exposure limit is needed. Class 3 solvents have PDEs of 50 mg or more per day. 17
  • 18. Residual Solvents Options for Describing Limits of Class 2 Solvents : Two options are available when setting limits for Class 2 solvents. Option 1: The concentration limits in ppm stated in ICH Q3C Guideline can be used. They were calculated using the formula given below, by assuming a product mass of 10 g administered daily. 1000 X PDE (mg/day) Concentration (ppm) = ---------------------------- dose (g/day) 18
  • 19. Residual Solvents Options for Describing Limits of Class 2 Solvents :… Option 2: The limits are calculated using the above formula based on the PDE reported in the ICH Q3C Guideline and the maximum daily dosage of the Drug substance. The limits calculated are acceptable provided that it has been demonstrated that the residual solvent has been reduced to the practical minimum. The limits should be realistic in relation to analytical precision, manufacturing capability. 19
  • 20. Limits of Residual Solvents Class 1 solvents : 20 Solvent Concentration limit (ppm) Benzene 2 Carbon tetrachloride 4 1,2-Dichloroethane 5 1,1-Dichloroethene 8 1,1,1-Trichloroethane 1500
  • 21. Limits of Residual Solvents Class 2 solvents : 21 Solvent Limit (ppm) Solvent Limit (ppm) Acetonitrile 410 2-Ethoxyethanol 160 Chlorobenzene 360 Ethyleneglycol 620 Chloroform 60 Formamide 220 Cyclohexane 3880 Hexane 290 1,2-Dichloroethene 1870 Methanol 3000 Dichloromethane 600 2-Methoxyethanol 50 1,2-Dimethoxyethane 100 Methylbutyl ketone 50 N,N-Dimethylacetamide 1090 Methylcyclohexane 1180 N,N-Dimethylformamide 880 N-Methylpyrrolidone 530 1,4-Dioxane 380 Nitromethane 50 Tetrahydrofuran 720 Pyridine 200 Tetralin 100 Sulfolane 160 1,1,2-Trichloroethene 80 Toluene 890 Xylene 2170 - -
  • 22. Limits of Residual Solvents Class 3 solvents : It is considered that amounts of these residual solvents of 50 mg per day or less (corresponding to 5000 ppm or 0.5% under Option 1) is acceptable. 22 Solvent Solvent Solvent Acetic acid Ethanol 3-Methyl-1-butanol Acetone Ethyl acetate Methylethyl ketone Anisole Ethyl ether Methylisobutyl ketone 1-Butanol Ethyl formate 2-Methyl-1-propanol 2-Butanol Formic acid Pentane Butyl acetate Heptane 1-Pentanol tert-Butylmethyl ether Isobutyl acetate 1-Propanol Cumene Isopropyl acetate 2-Propanol Dimethyl sulfoxide Methyl acetate Propyl acetate
  • 23. Limits of Residual Solvents Solvents for which No Adequate Toxicological Data was Found: No adequate toxicological data is found for the following solvents. 23 Solvent Solvent 1,1-Diethoxypropane Methylisopropyl ketone 1,1-Dimethoxymethane Methyltetrahydrofuran 2,2-Dimethoxypropane Petroleum ether Isooctane Trichloroacetic acid Isopropyl ether Trifluoroacetic acid
  • 25. Inorganic Impurities Introduction: Inorganic impurities can result from the manufacturing process. They are normally known and identified and include: Reagents, ligands and catalysts Heavy metals or other residual metals Inorganic salts Other materials (e.g., filter aids, charcoal) 25
  • 26. Control of Inorganic Impurities Control of the Impurities: Detected and quantified using pharmacopoeial or other appropriate procedures. Carry over of the catalysts to the API must be evaluated during the development stage. Inclusion/exclusion from the specification must be justified. Acceptance criteria must be based on pharmacopoeial or known safety standard. Controlled by the tests Heavy Metals, Sulfated Ash, test for specific metal…. 26
  • 27. Control of Inorganic Impurities Specification limit for Heavy Metals: As specified by Pharmacopeia wherever applicable. Specification limit where the product is not listed in the pharmacopoeia: 27
  • 28. Control of Inorganic Impurities Specification limit for Sulfated Ash: As specified by Pharmacopeia wherever applicable. When it is not listed in pharmacopoeia, must be specified as 0.1%, unless otherwise justified. Specification limit for Metal Catalysts: Must be specified inline with the EMEA guideline on metal Catalysts. If the metal is not listed, must specify based on the available toxicology data or any other guidance. 28
  • 29. Control of Inorganic Impurities Specification limit for some of the metal Impurities: *The total amount of listed metals should not exceed the indicated limit (Reference: EMEA Guideline for specification limits for metal resides) 29 Classificatio n Oral Exposure Parenteral Exposure PDE (µg/day) Conc. (ppm) PDE (µg/day) Conc. (ppm) Class IA: Pt, Pd 100 10 10 1 Class 1B*: Ir, Rh, Ru, Os 100 10 10 1 Class 1C: Mo, Ni, Cr, V 250 25 25 2.5 Class 2: Cu, Mn 2500 250 250 25 Class 3: Fe, Zn 13000 1300 1300 130
  • 30. Specification limit for Non-API related impurities not listed in ICH Q3C Guideline Setting the specification limit for the Solvents or Reagents (Not related to API) not listed in ICH Q3C Guideline 30
  • 31. Specification limit for Non-API related impurities not listed in ICH Q3C Guideline Introduction: The specification limit for the solvents or reagents which are not listed in ICH Q3C must be determined based on the Toxicological data. Formula for the calculation of the impurity is given in the next slide: 31
  • 32. Specification limit for Non-API related impurities not listed in ICH Q3C Guideline Methods for Establishing Exposure Limits: Acceptable exposure levels is calculated from the PDE values inline with the procedure given in ICH Q3C Guideline as below: 1000 X PDE (mg/day) Concentration (ppm) = ---------------------------- dose (g/day) 32
  • 33. Specification limit for Non-API related impurities not listed in ICH Q3C Guideline Calculation of the PDE Value: Where PDE value is not available, PDE is derived from the no-observed-effect level (NOEL), or the lowest- observed effect level (LOEL) in the most relevant animal study as follows: NOEL x Weight Adjustment PDE = ------------------------------------- F1 x F2 x F3 x F4 x F5 33
  • 34. Specification limit for Non-API related impurities not listed in ICH Q3C Guideline Calculation of the PDE Value:… F1 = A factor to account for extrapolation between species. F2 = A factor of 10 to account for variability between individuals. F3 = A variable factor to account for toxicity studies of short- term exposure. F4 = A factor that may be applied in cases of severe toxicity, e.g. non-genotoxic carcinogenicity, neurotoxicity or teratogenicity. F5 = A variable factor that may be applied if the no-effect level was not established. 34
  • 35. Specification limit for Non-API related impurities not listed in ICH Q3C Guideline A typical calculation for Establishing Exposure Limits (Specification Limit) is attached. 35
  • 36. References References: IMPURITIES IN NEW DRUG SUBSTANCES Q3A. IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Q3C. GUIDELINE ON THE SPECIFICATION LIMITS FOR RESIDUES OF METAL CATALYSTS OR METAL REAGENTS. 36